

Amman-SESAME-JSPS - October 2002

Structural Biology & Genomics
Research at Daresbury


Samar Hasnain

**Molecular Biophysics Group
&**

**College Of Biology & Medicine
Daresbury Laboratory**

<http://www.srs.dl.ac.uk/mbg/>


<http://www.nwsgc.ac.uk/>






Impact of SRS, Daresbury, on UK structural biology


NWSGC



SRS performance in comparison with other major SR facilities 1996-99



Nitrite Reductase



A blue Cu protein from *Alcaligenes xylosoxidans* containing type 1 and type 2 Cu centres.



Biologically important as part of the denitrification pathway


36.5kDa protein containing 336 residues

Type 1 Cu is electron donor
Type 2 Cu is catalytic site




NiR Captures Covers of Recent Journals






Murphy, L. M. et al.,
(2002) *J. Mol. Biol.*,
315, 859-871



Murphy, L. M. et al.,
(2002) *J. Mol. Biol.*,
315, 859-871

Type 1 and Type 2 Copper Centres




Map contoured at 2σ

Why Metalloproteins & Atomic Resolution?


- **Metalloproteins make up some 30% of known genomes.**
- **Redox & ligand chemistry of biological metals is exploited to perform a wide variety of chemical reactions.**
- **To understand how the chemistry of metals is utilised to perform a particular function, very high resolution structural data are imperative.**
- **Small changes at the metal centre and its ligands can be amplified by the protein to perform complex biological processes. This is most beautifully illustrated in the case of Haem proteins where small changes at the Fe results in large changes elsewhere which control the allosteric mechanism.**
- **Despite tremendous efforts, only a few crystallographic structures are available at atomic resolution i.e. $<1.2\text{\AA}$.**

Resolution of Cu-protein Structures in the PDB




In situ Annealing of NiR Crystals

Before



**Resolution ~2Å
Mosaicity 1.5°
Slightly twinned**

After



**Resolution 1.04Å (refined)
Mosaicity 0.33°
Twinning lost**

Ellis MJ, et al., (2002) *Acta Cryst.* D58, 456-458

Structures Determined

Native Protein 1.04Å resolution SRS Stn. 14.2

Highest resolution structure of any multicopper oxidase

Recombinant Protein 1.15Å resolution SRS Stn. 9.6

Apo-Recombinant 1.9Å resolution PF BL6A

Regulation of T1 Cu Redox Potential

Met144Ala 2.2Å resolution SRS Stn. 9.6

Met144Gln 1.9Å resolution SRS Stn. 9.6

Met144Leu 1.9Å resolution SRS Stn. 9.6

Electron Gating from T1 Cu to T2 Cu

Cys130Ala 1.35Å resolution SRS Stn. 9.6

His129Val 1.9Å resolution SRS Stn. 9.6

Coupling of Redox Centres - Proton abstraction

Asp92Asn 1.9Å resolution SRS Stn. 9.6

Asp92Glu 1.12Å resolution SRS Stn. 9.5

Proton Pumping


His254Phe 1.85Å resolution SRS Stn. 9.5

inactive

reduced activity compared to native

increased activity compared to native

Benefits of Atomic Resolution : Map Quality



2Å resolution
25023 reflections




1.5Å resolution
58428 reflections



1.04Å resolution
161347 reflections

Benefits of Atomic Resolution: **Hydrogen Atom Positions**




(Nitrite reductase at 1.04Å)

Benefits of Atomic Resolution: Accuracy of Metrical Information

NiR type 2 Cu site EXAFS: simulations using crystallographic coordinates



1.90 Å resolution (1hau.pdb)

Fit index = 5.4





1.04 Å resolution

Fit index = 0.6





Coupling of Redox Centres





Strange RW, et al., (1999) *J. Mol. Biol.* **287**, 1001-1009

Proton Pump



Ellis MJ, et al., (2002) *J. Mol. Biol.* **316**, 51-64

Proton abstraction - D92E Mutation




Mutation Asp92Glu has no activity.


Glu92 directly ligates T2Cu - preventing NO₂⁻ from co-ordinating to T2Cu.

Wat* moves 6Å from position in native enzyme breaking H-bonded water network.


Wat at T2Cu is highly disordered due to Glu92 co-ordination




Crystals of NiR




D92E 1.1Å resolution




Native 3Å resolution



C130A 1.35Å resolution




**Native
5Å
resolution**



**Native 1.04Å
resolution**

Combined CD/X-ray Scattering study of Rusticyanin - a type I “blue” Cu protein




extreme properties of rusticyanin: *high redox potential* (680 mV) and *tolerance of a wide pH range* (ca 1.5-10)

Does the N-terminal “belt” make the protein acid-stable?

Circular-Dichroism Spectroscopy

**-35 mutant
does not bind
copper and is
soluble only at
pH5 or lower**




Fit Results


	wild type	-35 mutant
helix	6%	0%
strand	39%	53%
turn	15%	11%
“other”	40%	36%

*folded
into
 β -barrel*

The Molecular Biophysics Group




North West Structural Genomics Centre



- **Structural Genomics** is a new and rapidly growing interdisciplinary research aimed at extending the vast array of genomic sequence data with a comparable, systematic database of protein structures
- **Synchrotron Radiation based X-ray Crystallography** is unique in providing very accurate high resolution structures of proteins and their complexes
- Worldwide, structural genomics has been made possible by recent rapid progress in several related key technologies. These include synchrotron based MAD (**Multiple wavelength Anomalous Dispersion**) phase determination, cloning and recombinant expression, genome sequencing projects and bioinformatic methods of fold assignment and function prediction
- **In early 2000**, a consortium of several groups in the North West of England proposed the establishment of a structure genomics centre (**NWSGC**) to exploit the unique resources offered by their close proximity to the UK's current **synchrotron radiation source (SRS)**


- **NWSGC** members have brought together expertise in X-ray protein crystallography, pathogens biology, membrane proteins, metalloproteins and thus initiated the **first structural genomics effort in the UK**.
- In summer 2001, the **Leeds** Bioinformatics group joined.
- In July 2001, UK's research councils (**BBSRC, EPSRC & MRC**) funded a **5 year grant** "NW STRUCTURE GENOMICS CENTRE'S HIGH THROUGHPUT MAD BEAMLIN FOR *PATHOGENS GENOMES*" with NWSGC having 67% share in years 4 &5.
- NWSGC has selected to join the **International TB Structural Genomics effort** and has established close links with the **RIKEN structural genomics programme**.
- June 2002, we are participating in two EOI's for EU framework VI proposal; one entitled '**Tuberculosis Drug Development**' and other entitled '**Structural Genomics of Metalloproteins : Function and Mis-function**'.

TB incidence per 100,000 people



Mycobacterium tuberculosis

- 1/3 of world population currently infected
- 5-10% infective people develop symptoms
- TB kills ~3 million people each year. 8 million annually develop symptoms
- **India** has the highest incidence of TB (about 1.83 million cases in 1998) and accounts for 23% of the world's cases.
- **China** is a close second with about 1.41 million cases or 17% of the world's cases.



- Globally, 8% of TB cases are due to HIV
- in sub-Saharan Africa the figure has risen to 80%.

- TB is resistant to a range of antibiotics
- Cell membrane acts as permeability Barrier
- Contains drug modifying enzymes

- Vaccine (BCG): important for control
- Improve efficacy by genetic manipulation
- Attenuated strains devoid of immunosuppressing genes

Researcher	Target	Protein	Status
Samar Hasnain	Rv0185	Hypothetical metalloprotein	Crystallising
	Rv2547	Hypothetical metalloprotein	Crystallising
	Rv2865	Hypothetical metalloprotein	Cloned (II)
	Rv0359	Hypothetical metalloprotein	Ligation
	Rv2776c	Probable oxidoreductase	Cloned (II)
	Rv0247c	Probable Iron-sulphur protein	Ligation
	Rv2718c	Probable metalloprotein	Cloned (II)
John Helliwell	Rv0510	hemC, porphobilinogen deaminase	Targeted
	Rv3307	deoD, purine nucleoside phosphorylase	Targeted
Jordi Bella	Rv0171	Part of mce1 operon	Ligation
	Rv1693	Hypothetical protein	Ligation
	Rv1942c	Conserved hypothetical protein	Ligation
	Rv2305	Hypothetical protein	Ligation
	Rv3070	Unknown membrane protein	Ligation
Colin Reynolds	Rv3852	Histone like protein	Targeted
	Rv2986c	Histone like protein	Ligation
	Rv1388	Integration host factor	Targeted
	Rv1407	Similar to other Fmu proteins	Targeted

Researcher	Target	Protein	Status
Lydia Tabernero	Rv0153c	Putative tyrosine-phosphatase	Ligation
	Rv0505c	serB, probable phosphoserine phosphatase	Ligation
	Rv196	part of mce3 operon	Ligation
	Rv2234	ptpA, tyrosine-phosphatase	Ligation
	Rv3042c	serB2, phosphoserine phosphatase	Ligation
	Rv3628	ppa,inorganic phosphatase	Ligation
	Rv3867	conserved hypothetical protein	Cloned (II)
Mark Ellis	Rv2060	Conserved hypothetical protein	Ligation
	Rv2229c	Putative zinc metalloprotein	Ligation
	Rv2711	ideR, iron dependent repressor	Cloned (II)
	Rv3207c	Putative zinc metalloproteinase	Expressed
	Rv3836	Putative zinc metalloproteinase	Expressed
Michele Cianci	Rv3717	Involved in cell biosynthesis	Targeted
	Rv3919	Involved in cell biosynthesis	Targeted
	Rv2981c	Involved in cell biosynthesis	Targeted
	Rv3712	Involved in cell biosynthesis	Targeted


Beamline 10 Statistics

Peak Field	2.4 T
Period	220 mm
Number of Full Strength Poles	9
End Pole Field	1.9 T
Number of End Poles	2
Minimum Magnet Gap	20 mm
Flux at 12.7 keV	4×10^{13}
Flux Advantage over SRS BM	x ~60

Magnet array ready for mounting on MPW drive mechanism



Structure Determination Centre






Co-operative development with **NWSGC**



Daresbury Laboratory



International Advisory Committee

Sung Ho Kim (Berkeley)


Udo Heinemann (Berlin)

Thomas C. Terwilliger (Los Alamos)

Yoshiyuke Yokoyama (RIKEN)

Joint Coordinators

Samar Hasnain & John Helliwell



Tuberculosis Drug Development

Ken Duncan, GlaxoSmithKline, UK (Coordinator)
Rui Appelberg, University of Porto, Portugal
Gregory Bancroft, LSHTM UK
Clifton Barry, National Institutes of Health, USA
Gurdyal Besra, Birmingham, UK
Pere-Joan Cardona, Barcelona, Spain
Kelly Chibale, University of Cape Town, South Africa
Stewart Cole, Institut Pasteur, France
Jacques Eustache, Ecole Nationale, France
Alfonso Fernández-Mayoralas, C.S.I.C. Madrid, Spain
Rob Field, University of East Anglia, UK
Jacques Grosset, Paris, France
Samar Hasnain, Daresbury Laboratory, UK
John Helliwell, Daresbury Laboratory, UK
Federico Gomez de las Heras, GlaxoSmithKline, UK
Lise-Lotte Gundersen, University of Oslo, Norway
Danijel Kikelj, University of Ljubljana, Slovenia
Eddy Littler, Medivir, Sweden
Shekhar Mande, Hyderabad, India
Tanya Parish, Barts and London, UK
Neil Stoker, Royal Veterinary College, UK
Jochen Wiesner, Jomaa Pharmaka GmbH, Germany
Douglas Young, Imperial College, UK

Core Members of SGEMET consortium.

Astex Technology, UK (*Blundell & Jhoti*)

Institut de Genetique Humaine ,CNRS Montpellier (*Lehmann*)

Leiden University, Netherlands (*Canthers*)

The Max-Planck-Institut for Biochemistry, Munich (*Messerschmidt*)

MRC Prion Unit, London, UK (*Collinge*)

The North West Structural Genomics Centre, UK (*Hasnain & Helliwell*)

Oxford University and OCMS, (*Schofield*)

Italy (*Bertini, Banci, Luchinat*).

The University of Grenoble (*Fontecave*)

The University of Heidelberg, Germany (*Multhaup*).

The University of Upsalla, Sweden (*Hajdu & Eriksson*).

The University of Leuven (*Robberecht*)

The Universidade Nova de Lisboa, Portugal (*Moura*).